澳门太阳集团www7722138-首页|welcome

Research and Development
Strong, Innovation-driven R&D Capabilities
R&D Field
Cancer Types Covered by the R&D Pipeline
 
  • Lung
    Cancer
  • Breast
    Cancer
  • Gastric
    Cancer
  • Nasopharyngeal
    Cancer
Rich and Balanced Pipeline
Updated in February 2022
 
  • 14 Oncology+Non-oncology compounds in core pipeline, including those in late clinical stage and pre-clinical stage
  • The compound targets in the late stage of development have been well-validated
  • Multiple potential best-in-class compounds are expected to be used in combination to treat major indications
Outstanding Talent
  • Leading scientists with outstanding achievements
  • Rich experience in successful drug approval & launch
  • Covering the entire span of oncology research and development
R&D Pipeline
Oncology
 

Non-oncology
 

Pipeline
Target

Microtubule Stabilizer

Indication

Gastric Cancer

  • Stage

    Pre-clinical 

     
  •  

    Phase I

     
  •  

    Phase II

     
  •  

    Key Phase II/Phase III

     
  •  

Breast Cancer

  • Stage

    Pre-clinical 

     
  •  

    Phase I

     
  •  

    Phase II

     
  •  

    Key Phase II/Phase III

     
  •  

Solid Tumors(Combination Therapy)

  • Stage

    Pre-clinical 

     
  •  

    Phase I

     
  •  

Commercial Right

Greater China 

Profile

TCM

Reduce wound inflammation Increase epithelialization of epidermal tissues Promote collagen production Reduce formation of wound granulation tissues

Target

N/A

Indication/
Potential
indication

Diabetic Foot Ulcer

  • Stage

    Pre-clinical

  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

     
  •  

    NDA

Profile

Oral small molecule TKI targeting FGFR1-3, VEGFR1-3, PDGFR α/β, with significant efficacy and high safety Rapid oral absorption, with little food effects on PK Pivotal Phase II study ongoing in multiple sites nationwide for the treatment of various types of tumors Explore combinations with PD-1/PD-L1 antibody

Target

FGFR1-3

Indication/
Potential
indication

Thymic Cancer

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

  •  

    NDA

Target

VEGFR1-3

Indication/ Potential indication

Nasopharyngeal Carcinoma

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

  •  

    NDA

Target

PDGFR α/β

Indication/ Potential indication

Small Cell Lung Cancer

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

  •  

    NDA

Profile

Clinical development strategy guided by unique biomarkers High selectivity to c-Met and long half-life Multiple studies ongoing in China/Japan/US; preliminary clinical efficacy hasbeen observed, with good safety

Target

c-Met

Indication/ Potential indication

Exon-14 Skipping in Non-small Cell Lung Cancer

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

  •  

    NDA

c-Met Mutation in Non-small Cell Lung Cancer

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

  •  

    NDA

c-Met Mutation in Non-small Cell Lung Cancer

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

  •  

    Phase 3

  •  

    NDA

Profile

Highly active PI3Kα inhibitor Clinical development strategy guided by unique biomarkers Significant in vivo/vitro anti-tumor effects Preferable safety profile with little and reversible glycemia effects

Target

c-Met

Indication/
Potential indication

Solid tumor

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

  •  

    Phase 3

  •  

    NDA

Solid tumor

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

  •  

    Phase 3

  •  

    NDA

Breast Cancer

  • Stage

    Pre-clinical

     
  •  

    Phase 1

     
  •  

    Phase 2

  •  

    Phase 3

  •  

    NDA

Follow Us
©2020 Haihe Biopharma Co., Ltd.
All Rights Reserved 沪ICP备12016151号-1